Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Darel, Martínez"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. Outstanding results in hematological malignancies and encouraging pre-clinical anti-tumor activity against a wide
Externí odkaz:
https://doaj.org/article/451367ddc3494d2ab73eff4cfb3ff481
Autor:
Darel Martínez-Bedoya, Ana M Hernández-Vázquez, Teresa Rondón-Corrales, Tania Griñán-Ramirez, Nely Rodríguez-Zhurbenko, Amaury Pupo-Meriño, Lianet Cabrera-López, Judith Raymond-Pous, Ana M Vázquez-Gallo, Rolando Pérez-Rodríguez
Publikováno v:
Biotecnología Aplicada, Vol 35, Iss 2, Pp 2511-2513 (2018)
Externí odkaz:
https://doaj.org/article/61b21709e8b84bf2932832d587700ba7
Autor:
Darel Martínez, Amaury Pupo, Lianet Cabrera, Judith Raymond, Nichol E. Holodick, Ana María Hernández
Publikováno v:
Journal of Immunology Research, Vol 2017 (2017)
P3 is a murine, germline, IgM mAb that recognizes N-glycolylated gangliosides and other self-antigens. This antibody is able to induce an anti-idiotypic IgG response and B-T idiotypic cascade, even in the absence of any adjuvant or carrier protein. P
Externí odkaz:
https://doaj.org/article/4bc5ddab6ff3485db5da05270d54eb98
Autor:
Darel Martínez Bedoya
Publikováno v:
Revista Cubana de Investigaciones Biomédicas, Vol 31, Iss 4, Pp 417-428 (2012)
La liberación controlada de fármacos en el sitio del tumor y el desarrollo de técnicas no invasivas de monitoreo constituyen 2 de los principales retos que enfrentan las terapias antitumorales en la actualidad. En este trabajo se analizan algunas
Externí odkaz:
https://doaj.org/article/d716d670189b4cff9715015611b768d7
Autor:
Dasha Fuentes, Alejandro Cabezas-Cruz, Circe Mesa, Tania Carmenate, Darel Martínez, Anet Valdés-Zayas, Enrique Montero, Rolando Pérez
Publikováno v:
Journal of Breast Cancer. 25:218
The F3II cell line is a highly invasive variant of mammary carcinoma. Although it is frequently used as a model to evaluate the efficacy of immunotherapy, its impact on the immune system remains poorly understood. The main objectives of this study we
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2086
Chimeric antigen receptor (CAR) T cell therapies are ex vivo manufactured cellular products that have been useful in the treatment of blood cancers and solid tumors. The quality of the final cellular product is influenced by several amenable factors
Publikováno v:
Methods in Molecular Biology ISBN: 9781071601457
Chimeric antigen receptor (CAR) T cell therapies are ex vivo manufactured cellular products that have been useful in the treatment of blood cancers and solid tumors. The quality of the final cellular product is influenced by several amenable factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::325309cc011296b7e6ebb285151a1634
https://doi.org/10.1007/978-1-0716-0146-4_15
https://doi.org/10.1007/978-1-0716-0146-4_15
Autor:
Orlando Morales, Adriana Carr, Damián Blanco, Mercedes Cedeño, Rancés Blanco, Enrique Rengifo, Darel Martínez, Charles E. Rengifo, Carmen Viada, Elizabeth Domínguez
Publikováno v:
Pathology Research International, Vol 2015 (2015)
Pathology Research International
Pathology Research International
The prognostic role of N-glycolyl GM3 ganglioside (NeuGcGM3) expression in non-small cell lung carcinoma (NSCLC) still remains controversial. In this study, the NeuGcGM3 expression was reevaluated using an increased number of NSCLC cases and the 14F7
Autor:
Darel Martínez, Maura Rabade-Chediak, Nely Rodríguez-Zhurbenko, Ana María Hernández, Tania Griñán
Publikováno v:
Annals of the New York Academy of Sciences. 1362:224-238
While not naturally expressed in normal human tissues, N-glycolylated (NeuGc) gangliosides are overexpressed in several tumors and have immunosuppressive capacity, which contributes to cancer progression. Naturally occurring antibodies against NeuGcG